Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Announces Early Access Program for Imaging Mass Cytometry Platform

Premium

NEW YORK (GenomeWeb) – Fluidigm this week announced that it plans by the end of the year to launch an early access program for its upcoming imaging mass cytometry platform.

Based on Fluidigm's CyTOF mass cytometry platform and research by University of Zurich researcher Bernd Bodenmiller, the platform allows users to obtain spatial and expression information on up to 30 proteins simultaneously at the single-cell level, the company said.

This "extension of mass cytometry combines an upfront laser ablation module with the CyTOF platform," Gajus Worthington, Fluidigm president and CEO, said in a statement. "This will enable scientists to track protein identity, quantity, and location within a tissue sample, allowing entirely new studies of cellular heterogeneity and function.”

Fluidigm has begun accepting applications for early access to the device.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.